Replies to post #32575 on RespireRx Pharmaceuticals Inc (fka RSPI)

[haysaw]

As always, Athero, there are two sides to a coin. Take for instance this author's quote (from the article interviewing the Astra Zeneca CEO, which I just posted to MF4 today):

"Big pharma" is changing and devoting fewer resources to scientists, for various reasons. Drugs companies have woken up to the idea of licensing agreements, where they can pay smaller biotechnology companies to develop potential treatments at a fraction of the cost.

BP's R&D loss should be biotech's gain--with potentially far less waste in resources.